Search clinical trials for: SHR3680; SHR3162

Total 100 results

Atridia Pty Ltd.

Completed

A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer

Prostate Cancer | Neoplasm

Australia
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

Prostate Cancer | Castration-resistant Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC

Prostate Cancer Castration-resistant Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects

Healthy Adult Male and Female Volunteers
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients

Hormone Refractory Prostate Cancer | Metastatic Prostate Carcinoma

China
Atridia Pty Ltd.

Completed

A Trial of SHR3162 in Healthy Caucasian Volunteers

Healthy Volunteers

Australia
Atridia Pty Ltd.

Completed

A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors

Solid Tumors | Neoplasm

Australia
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Relative Bioavailability Study of SHR3680 (SHR-3680)

Healthy Male Subjects

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects

Castration-Resistant Prostate Cancer

China
Fudan University

Recruiting

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (MULAN)

Breast Cancer | Metastatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Prostate Cancer | Castration-resistant Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer

Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

Hepatic Impairment | Healthy Participants

China
The Affiliated Hospital of Qingdao University

Completed

A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers

Healthy Volunteers

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

Prostate Cancer Metastatic

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

China
Fudan University

Not yet recruiting

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

TNBC - Triple-Negative Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects

Healthy Volunteers

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets

Endometriosis, Uterine Fibroids, Male Hormone-sensitive Prostate Cancer, Assisted Reproduction

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR6390 in Healthy Adult Male Volunteers

Healthy Adult Male Volunteers

China
Atridia Pty Ltd.

Completed

A Single Dose Study of SHR4640 in Healthy Male Volunteers

Gout

Australia
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects

Hyperuricemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR6390 in Advanced Solid Tumor Patients

Neoplasm

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study on the Food Effects of Oral SHR4640 Tablets in Healthy Volunteers

Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers

Hyperuricemia | Primary Gout
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Unknown

A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients

Melanoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects

Hyperuricemia

China
Atridia Pty Ltd.

Completed

A Trial of SHR6390 in Healthy Caucasian Volunteers

Healthy Volunteers

Australia
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer

Gastric Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study to Evaluate the Mass Balance of [14C]SHR7280 in Healthy Adult Volunteers

Assisted Reproduction

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Identify Effective Doses of SHR7280 Tablets in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)

Female Subjects Undergoing COH in ART to Prevent Early Ovulation

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer (DAP-Her-01)

Metastatic Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers.

Healthy Adult Male Volunteers

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Multiple Dose Study of SHR4640 in Healthy Subjects

Gout; Hyperuricemia

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of SHR6390 in Renal Insufficiency and Healthy Subjects

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer

ER+ / HER2- Advanced Breast Cancer

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Metastatic Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer

Hormone Sensitive Prostate Cancer

China
Beijing 302 Hospital

Not yet recruiting

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

HR+/HER2- Advanced Breast Cancer

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer

ER-Positive, HER2-Negative Breast Cancer

China
Harbin Medical University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC

HCC | NSCLC | CRC
Tianjin Medical University Second Hospital

Unknown

A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）

Small Cell Lung Cancer Extensive Stage

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia

Hyperuricemia
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment

Hepatic Impairment

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

Hepatic Impairment | Healthy Participants
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

The Pharmacokinetic(PK)/Pharmacodynamics(PD) Study of SHR7280 Tablets in Premenopausal Subjects With Endometriosis.

Endometriosis

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The PK/PD Study of SHR7280 Tablets in Healthy Subjects.

Healthy Subjects

China
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Completed

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Ovarian Cancer | Triple Negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia

Primary Gout and Hyperuricemia

Search clinical trials for: SHR3680; SHR3162

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations